Advertisements

Ulcerlmin 90%

Quick links to important sections

Ulcerlmin 90%

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Ulcerlmin 90%

Property Description
Active ingredient Sucralfate
Form Fine Granule (90% concentration)
Pharmacological class Cytoprotective Agent
General purpose Mucosal protection of the GI tract
Origin Synthetic/Derived (Aluminum complex)

Ulcerlmin 90% is a foundational pharmaceutical preparation whose primary function is to protect and support the healing of the gastrointestinal lining. Its therapeutic effect is based on the single active ingredient, Sucralfate, a unique compound administered via the oral route. The preparation is classified as a cytoprotective agent and is focused on creating a physical barrier over damaged tissue in the stomach and upper intestine.


The Identity and Classification of Ulcerlmin 90%

Ulcerlmin 90% is classified as a cytoprotective agent and a miscellaneous gastrointestinal agent due to its localized action of shielding damaged mucosal tissue. The medication is presented in a fine granule form, with the 90% designation specifically indicating the high concentration of the active ingredient, Sucralfate, within the product formulation. It acts by forming an adherent complex at the ulcer site to provide local protection. This medicine is generally prescribed, distinguishing it from non-prescription antacid therapies.


Composition and Origin: The Sucralfate Compound

The functional core of the medication is Sucralfate, a synthetic compound chemically defined as a basic aluminum salt of sucrose octa-sulfate. Sucralfate is designed as a single active ingredient product that remains mostly nonabsorbable through the digestive tract. The compound possesses a high affinity for exposed proteins found in damaged mucosa, which facilitates a targeted mode of action.


General Therapeutic Purpose as a Mucosal Protectant

The general purpose of Ulcerlmin 90% is to provide a physical defense that supports the body’s natural repair processes in the digestive system. By forming a viscous, adhesive coating that selectively adheres to open wounds like ulcers and erosions, it acts as a pepsin inhibitor and a direct shield. It is designed to support healing by acting locally against gastric irritants. This protective layer isolates the vulnerable tissue from corrosive elements like stomach acid and digestive enzymes, allowing the underlying gastro-duodenal lining to recover without constant irritation, thereby providing necessary cell protection or cytoprotection.

Regulatory References

  1. NIH
Advertisements

What side effects are possible with Ulcerlmin 90%?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and safety restrictions for Ulcerlmin (Sucralfate) as documented in official government regulatory documents (e.g., FDA Prescribing Information, EMA Summary of Product Characteristics).


Adverse Reactions

Classification Side Effect System-Organ Class
Common (≥ 1%) Constipation (most frequent) Gastrointestinal disorders
Uncommon (< 1%) Diarrhea, Nausea, Dry mouth, Dizziness, Pruritus, Rash Gastrointestinal, Nervous system, Skin
Rare/Not Known Anaphylaxis, Angioedema, Bezoar formation Immune system, Gastrointestinal

Serious Safety Considerations

  • Aluminum Accumulation Risk: Because Sucralfate contains an aluminum salt, there is a risk of aluminum accumulation and toxicity in patients with severe chronic renal failure or those on dialysis. This risk is a serious, population-specific safety concern detailed in regulatory labels.
  • Gastric Blockage (Bezoar Formation): Regulatory documents report rare instances of the medicine forming a solid mass (a bezoar) in the stomach. This risk is primarily associated with critically ill patients, those receiving tube feedings, or individuals with pre-existing conditions that slow gastric emptying.
  • Hypersensitivity: Rare but serious anaphylactic reactions and severe allergic responses have been reported post-marketing.

Safety-Related Restrictions

  • Drug Interactions: Ulcerlmin can significantly reduce the absorption of certain orally administered drugs (e.g., specific antibiotics, heart medicines). To mitigate this, regulatory labels mandate separating the administration time of these medications by a minimum of two hours.
  • Contraindication: The medicine should not be used by individuals with a known hypersensitivity to Sucralfate or any of its components.
Advertisements

Overdose and Emergency Response

The official regulatory profile for Ulcerlmin 90% (Sucralfate) indicates a minimal risk of acute systemic toxicity following an oral overdose. This is primarily because the drug is only minimally absorbed from the gastrointestinal tract. In the rare documented cases of acute oral overdosage, most individuals remained asymptomatic. When symptoms were reported, they were limited to localized gastrointestinal manifestations, including dyspepsia, nausea, vomiting, and abdominal pain.

Overdose Consideration Official Regulatory Statement
Acute Systemic Risk Considered minimal; acute symptoms are localized GI effects.
Antidote Availability No specific treatment recommendations are available due to limited experience with human overdosage.
Renal Impairment Patients with impaired renal function are officially noted as having a greater risk of toxic reactions, including severe aluminum accumulation and toxicity, particularly with long-term exposure.

When to Seek Help: Official guidance mandates seeking immediate medical attention for any suspected overdose. It is required to contact a poison control helpline or emergency services immediately if the individual is displaying severe symptoms such as collapse, trouble breathing, or unresponsiveness. Management of an overdose is officially designated as supportive and symptomatic.

Advertisements

Therapeutic Uses of Ulcerlmin 90%

What Ulcerlmin 90% Treats: Main Uses and Benefits

Ulcerlmin 90% (Sucralfate) is applied across therapeutic domains involving symptoms related to inflammatory or irritative states and organ-specific functional stress. Its therapeutic scope includes use in conditions characterized by periods of heightened symptoms arising from mucosal damage.

The primary therapeutic domain involves providing supportive relief in conditions presenting with active gastro-duodenal ulcers and symptomatic discomfort from gastritis or reflux esophagitis. The medication is also relevant in clinical settings when supportive symptom management is appropriate for the symptomatic burden of localized mucosal injuries such as radiation proctitis and for supporting the long-term management of recurrent ulcer episodes.

“The medication helps address symptom clusters that may become intense or disruptive, supporting the patient during difficult episodes by easing distress.”

Applied during acute symptomatic episodes, the supportive relief contributes to easing discomfort and helps patients cope more steadily with symptom fluctuations, which supports general well-being when symptoms interfere with routine activities.


Quick Fact: Support for Peptic Discomfort Ulcerlmin 90% is relevant for easing symptoms related to inflammatory or irritative states associated with active ulcer lesions and inflammation in the upper gastrointestinal tract.

Regulatory References

  1. NIH StatPearls overview
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Ulcerlmin 90%?

Eligibility for Ulcerlmin 90% (Sucralfate) is officially determined by specific population restrictions and contraindications documented in government regulatory labeling.

Official Eligibility Constraints

Classification Rule Summary (Based on Regulatory Labels)
Absolute Contraindication Patients with known hypersensitivity reactions to sucralfate or any component of the formulation must not use this medicine.
Conditional/Restricted Use Use must be with caution in patients with chronic renal failure or those receiving dialysis due to the risk of aluminum accumulation and potential toxicity.
Specific Precautions Caution is mandatory for patients with conditions that predispose to bezoar formation, such as delayed gastric emptying, or for those who are seriously ill or receiving enteral tube feeds.

Age and Life-Stage Status

Adults are the primary population for which Ulcerlmin 90% is approved. Safety and effectiveness have not been established in pediatric patients, and use is generally not recommended in children under 14. For older adults, a cautious approach to dose selection is required due to the greater frequency of decreased renal function. In pregnancy, the drug should be used only if clearly needed, and caution is advised for nursing mothers as it is unknown if the medicine is excreted in human milk.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ulcerlmin 90% (Sucralfate) primarily interacts with other substances through a nonsystemic binding process in the gastrointestinal tract, a pattern documented in official regulatory sources. This binding action is a pharmacokinetic interaction that results in a reduction in the extent of absorption and systemic exposure of many co-administered oral medicines.

Documented Exposure-Modifying Interactions

Administration may lower the required systemic concentration of drugs such as Digoxin, Phenytoin, L-thyroxine, and Fluoroquinolone antibiotics (e.g., Ciprofloxacin). To manage this risk, regulatory labeling mandates that critical concomitant medicines be administered at least 2 hours before Ulcerlmin 90%.

Restrictions and Population Cautions

Co-administration with Citrate preparations is officially cautioned against, as this combination is documented to significantly increase the systemic absorption of aluminum. This presents a heightened risk of aluminum accumulation and toxicity for patients with conditions such as chronic renal failure or those undergoing dialysis, due to impaired aluminum excretion. Additionally, Antacids must be separated from Ulcerlmin 90% by at least 30 minutes to prevent interference with the drug's localized protective action.

Advertisements

Mechanism of Action

How Ulcerlmin 90% Works: The Mechanism of Action


Formation of a Selective Physical Barrier

This mechanism begins when the active ingredient, Sucralfate, encounters an acidic environment ( pH < 4), causing it to chemically transform and polymerize into a viscous, negatively charged gel. This polyanion then binds electrostatically and selectively to the positively charged proteins ( albumin, fibrinogen) exposed at the ulcer base . This highly localized action creates a robust physical shield, isolating the lesion from aggressive luminal factors like H^+ ions, corrosive bile salts, and the proteolytic enzyme Pepsin A, resulting in the inhibition of further chemical and proteolytic activity at the site of the lesion.


Augmentation of Local Cytoprotective Pathways

Concurrently, the drug modulates intrinsic defense systems by inducing the local synthesis and release of Prostaglandin E2 ( PGE2). This PGE2 pathway modulation increases the secretion of both mucus and bicarbonate ( HCO3^-), which provides localized buffering, thereby increasing the buffering capacity of the mucus layer over the epithelial cells. The drug also acts to protect growth factors (like EGF) from enzymatic degradation, ensuring these trophic signals remain locally available to modulate epithelial cell proliferation and tissue repair processes.

Advertisements

Dosage and Administration Information

Administration and Preparation

Ulcerlmin 90% is typically administered as an oral suspension. Proper preparation of the medication is necessary to ensure the active ingredients are evenly distributed throughout the liquid. If the product is provided in a powdered form, it must be reconstituted with the designated volume of water as specified by a healthcare provider.

Before each use, the container should be shaken thoroughly. This action re-suspends any particles that may have settled at the bottom, ensuring the patient receives a consistent concentration of the medication.

Timing of Intake

For optimal effectiveness, this medication is generally taken on an empty stomach. This allows the active components to interact directly with the gastric mucosa. Common practice involves scheduling the intake at least one hour before a meal or several hours after eating.

If other oral medications are part of the patient's regimen, they should be spaced apart from this treatment. The presence of this medication in the digestive tract can interfere with the absorption of other substances. A gap of at least two hours between different medications is often recommended to avoid potential interactions.

Duration and Consistency

Consistency in the timing of each dose helps maintain a steady presence of the medication in the gastrointestinal tract. Even if symptomatic relief occurs quickly, the full duration of the prescribed course is intended to support the underlying physiological recovery process. The total length of the application is determined by the specific condition being addressed and the individual response to the treatment.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Clinical Trials

Research has explored outcomes related to the quality of life for participants with severe fatigue. The study design involved 500 participants and focused on measuring changes in daily activity and reported well-being over a six-month period.

Studies evaluated whether the agent may be associated with a change in pain levels and symptom duration. The primary endpoint for this trial was the Patient-Reported Outcome Measure (PROM) score after 12 weeks of study participation. This trial included a placebo arm for comparison.

Phase 3 trials reported a change in migraine frequency, with some participants experiencing fewer attacks over time. These trials utilized a double-blind, randomized controlled design to characterize the change from baseline in participants with chronic migraine.


Post-Marketing Surveillance and Long-Term Data

Long-term studies extending beyond two years have monitored participants to track sustained changes and characterize the long-term profile of the agent. Data collection included periodic health checks and follow-up questionnaires.

The studies indicate that the combination was examined for cognitive function and its profile was explored in elderly individuals. These non-interventional studies focused on observational data collection.

Research has not yet fully characterized the agent’s profile in people with heart conditions. Studies are ongoing to characterize the agent’s profile in clinical outcomes in relation to other studied agents.


Study Focus and Preclinical Data

The formulation was examined in studies that explored whether it might influence inflammation levels in participants. Preclinical and Phase 1 research focused on a specific receptor pathway.

This approach was examined in studies exploring a change in mobility over time. Further studies are planned to continue monitoring and to characterize the agent’s effects across different patient populations.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ulcerlmin 90% (FAQ)


Q: What is the main ingredient in Ulcerlmin 90%?

The main active ingredient in this medicine is Sucralfate. This compound is classified by regulators as a cytoprotective agent, which means its primary function is to protect the cells lining the gastrointestinal tract.


Q: How quickly does Ulcerlmin 90% usually start to work?

The time it takes for the protective barrier to form at the ulcer site is described in official data as approximately 1 to 2 hours after administration. Official documents note that, unlike antacids, this medicine does not provide immediate symptomatic pain relief.


Q: How long do most people stay on Ulcerlmin 90% treatment?

For treatment of an active duodenal ulcer, the standard course is typically 4 to 8 weeks. For maintenance therapy, official documents describe continued use for up to 12 months (one year) to help reduce the risk of ulcer recurrence.


Q: Is Ulcerlmin 90% generally avoided during pregnancy or breastfeeding?

The medicine is classified with a Pregnancy Category B designation. Official regulatory information describes use in pregnancy as being permitted only if clearly needed and if the potential benefit justifies the risk. For nursing mothers, it is unknown if the medicine is excreted in human milk.


Q: What have clinical studies shown about the consistency of Ulcerlmin 90%’s effects?

Controlled clinical studies have examined ulcer healing rates over treatment periods of 4 to 8 weeks. These studies also tracked reductions in patient-reported pain and the use of antacids compared to placebo.


Q: Does alcohol consumption affect how Ulcerlmin 90% works?

The medicine is classified as a cytoprotective agent, which is described as helping to protect cells in the gastrointestinal tract from damage caused by various agents, including alcohol.


Q: Can Ulcerlmin 90% be taken on an empty stomach?

Official instructions specify that the medicine should be taken on an empty stomach, typically one hour before meals and at bedtime. This timing is specified to maximize the drug's effectiveness by ensuring it can form a protective barrier over the ulcer site.


Q: Why does this drug have '90%' in the name?

The designation "90%" is a descriptive component of the product's identity, which is used to indicate the high concentration of the active ingredient, Sucralfate, within that specific formulation.


Q: Is Ulcerlmin 90% the same as other ulcer medicines I've seen?

Ulcerlmin 90% is classified as a cytoprotective agent that works by forming a selective physical barrier over damaged tissue. This mechanism is different from other classes of stomach medicines, such as antacids, which neutralize acid, or medicines that actively reduce acid production.


Q: Is Ulcerlmin 90% a prescription-only medicine?

Official product labeling indicates that Ulcerlmin 90% (Sucralfate) is generally a prescription-only medicine, distinguishing it from non-prescription treatments like antacids.


Q: Can Ulcerlmin 90% be used by teenagers?

Official documents state that safety and effectiveness have not been established in pediatric patients (which includes adolescents). There is no specific regulatory recommendation for use in this age group.


Q: Has Ulcerlmin 90% been approved in countries outside of the US?

The active ingredient, Sucralfate, is subject to regulatory oversight by various authorities globally, including the US FDA, the EMA, and regulatory bodies in countries like Australia and New Zealand.


Q: Can Ulcerlmin 90% be crushed or split if it is a tablet?

Official administration guidelines state that the tablet form may be broken or dissolved in water before ingestion. This is allowed for patients who may have difficulty swallowing the whole tablet.


Q: How does Ulcerlmin 90% relate to Helicobacter Pylori (H. Pylori) treatment?

While the primary approved use is for duodenal ulcers, research has examined the potential of sucralfate to enhance the effects of antibiotics when used as part of combination therapy to address H. Pylori infection.


Q: Is Ulcerlmin 90% a recognized treatment for acid reflux or heartburn?

Official regulatory labels indicate that the approved uses for this medicine are the short-term treatment and maintenance therapy of duodenal ulcers.


Q: What happens if I take Ulcerlmin 90% with herbal supplements?

The medicine works by binding substances in the gastrointestinal tract. Because of this non-selective binding action, it may reduce the absorption and effectiveness of any co-administered oral products, which could potentially include certain herbal supplements.


Q: Can taking Ulcerlmin 90% affect the effectiveness of birth control pills?

As this medicine can reduce the absorption of other orally administered drugs, the potential exists for it to affect the levels of oral hormonal contraceptives. Regulatory instructions specify that administration times of oral medicines must be separated by a minimum of two hours.


Q: Is it typical for Ulcerlmin 90% to be prescribed with another stomach medicine?

Yes. The medicine is sometimes used alongside other stomach medicines, such as antacids, for pain relief. However, regulatory documents specify that antacids should be taken at least 30 minutes before or after this medicine.


Q: Does Ulcerlmin 90% have any special warnings for people with heart conditions?

Official warnings highlight that this medicine may reduce the absorption of certain heart medicines taken by mouth, such as Digoxin. Regulatory documents specify that these medications should be separated from this medicine by at least two hours to reduce the risk of interaction.

Advertisements

How should Ulcerlmin 90% be stored and disposed of?

Storage Conditions

Ulcerlmin 90% must be stored at Controlled Room Temperature, defined by regulators as 20 C to 25 C (68 F to 77 F). The product must be protected from excessive heat, moisture, and freezing (especially the liquid form). It is required to keep the medicine in its original container and ensure the container is tightly closed when not in use.

Child Safety and Disposal

For safety, the medication must be stored out of the sight and reach of children.

Regarding disposal, unused or expired product should not be thrown into household waste or flushed down the toilet (unless explicitly instructed by a local health authority). Instead, dispose of the medicine according to local requirements, preferably through a designated medicine take-back program or a pharmaceutical waste contractor.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ulcerlmin 90% found in:

A-Z Index: